Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 3—March 2016
Dispatch

Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009–2014

Benoît Henry1, Matthieu Revest, Nathalie Dournon, Loïc Epelboin, Guillaume Mellon, Guillaume Bellaud, Pierre Mordant, Damien Le Dû, Nicolas Véziris, Christine Bernard, Sébastien Morel, Stéphane Jauréguiberry, Christian Michelet, François Bricaire, Pierre Tattevin2Comments to Author , and Éric Caumes2
Author affiliations: Centre Hospitalier Universitaire Pitié Salpêtrière, Paris, France (B. Henry, N. Dournon, L. Epelboin, G. Mellon, G. Bellaud, N. Véziris, C. Bernard, S. Morel, S. Jauréguiberry, F. Bricaire, E. Caumes); Université Pierre et Marie Curie, Paris (B. Henry, L. Epelboin, N. Véziris, S. Morel, F. Bricaire, E. Caumes); Centre Hospitalier Universitaire Pontchaillou, Rennes, France (M. Revest, C. Michelet, P. Tattevin); Hôpital Européen Georges Pompidou, Paris (P. Mordant); Université Paris Descartes, Paris (P. Mordant); Centre Hospitalier de Bligny, Briis-sous-Forges, France (D. Le Dû); Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris (N. Véziris, C. Bernard); Centre d'Immunologie et des Maladies Infectieuses, Paris (N. Véziris, S. Jauréguiberry); Université Rennes 1, Rennes (C. Michelet, P. Tattevin)

Main Article

Table 2

Anti-TB agents used in the treatment of persons with extensively drug-resistant TB, France, 2009–2014*

Drug No. patients previously treated with drug/no. with available data (%) No. patients with resistant strains†/no. with available data (%) No. study patients treated with drug/no. with available data (%)
Rifampin 12/15 (80) 20/20 (100) 0/20
Isoniazid 13/15 (86.7) 20/20 (100) 0/20
Pyrazinamide 14/15 (93.3) 15/17 (88.2) 9/20 (40)
Ethambutol 13/14 (92.9) 17/20 (85) 5/20 (25)
Streptomycin 6/14 (42.9) 19/20 (95) 0/20
Amikacin 3/14 (21.4) 10/20 (50) 12/20 (60)
Kanamycin 5/14 (35.7) 19/20 (95) 0/21
Capreomycin 9/15 (60) 16/20 (80) 2/20 (10)
Ofloxacin 4/14 (28.6) 20/20 (100) 0/20
Levofloxacin 3/12 (25) NA NA
Moxifloxacin 4/14 (28.6) 14/19 (73.7) 7/20 (35)
Ethionamide 9/15 (60) 17/20 (85) 5/20 (25)
Linezolid 0/14 0/20 20/20 (100)
p-aminosalicylate 14/17 (82.4) 4/20 (20) 16/20 (80)
Amoxicillin/clavulanate 3/14 (21.4) NA 19/20 (95)
Imipenem 0/14 NA 19/20 (95)
Cycloserine 12/15 (80) 16/21 (76.2) 13/20 (65)
Clarithromycin 2/13 (15.4) NA 0/21
Clofazimine 2/13 (15.4) NA 9/18 (50)
Bedaquiline 0/20 NA 16/20 (80)

*N/A, no available data; TB, tuberculosis.
†Determined by in vitro susceptibility testing at admission.

Main Article

1Current affiliation: Université Paris Descartes, Sorbonne Paris Cité, APHP, Hôpital Necker Enfants Malades, Centre d’Infectiologie Necker Pasteur, Institut Imagine, Paris, France.

2These senior authors contributed equally to this article.

Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external